相关临床试验
32
19 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
19
59.4%
已完成
8
25.0%
终止
1
3.1%
Unknown
4
12.5%
暂无批准数据
- Barts Health NHS Trust remained the UK's top recruiter to commercial drug trials for the seventh year running, enrolling 538 participants across 165 commercial trials in 2025/26. - Over 20,000 patients took part in research during 2025/26, with total research income reaching a record £90 million, including £20 million from commercial trials. - The Trust achieved 11 European or worldwide 'firsts' in patient recruitment and set up 57% of new studies within the national 90-day target. - Research-active organisations deliver better outcomes, giving patients earlier access to new treatments and technologies, according to R&D director Dr Jenny Rivers.
- Researchers at Queen Mary University of London have developed the first non-integrase strand-transfer inhibitor (INSTI) single tablet HIV treatment, combining doravirine with islatravir, addressing growing concerns about INSTI resistance in resource-limited settings. - The landmark phase 3 trial published in The Lancet demonstrates that the once-daily doravirine/islatravir combination shows similar efficacy and safety to current integrase inhibitor treatments. - The study recruited higher-than-usual numbers of women, older people, and racially minoritized adults, addressing chronic under-representation in HIV treatment trials. - Islatravir has long-acting potential and is being evaluated as the first weekly tablet for HIV treatment, representing a significant advancement toward more convenient dosing regimens.
- The NHS has approved enfortumab vedotin combined with pembrolizumab for bladder cancer patients, marking one of the most significant advances in decades for this difficult-to-treat disease. - Clinical trials demonstrated the combination therapy nearly doubles survival time from 1.5 years to over 2.5 years compared to standard chemotherapy for metastatic bladder cancer. - Approximately 1,250 patients annually in England will be eligible for this treatment, which also showed superior response rates with 30% achieving undetectable cancer levels versus 12.5% with chemotherapy. - The dual-mechanism approach targets cancer cells directly while simultaneously boosting immune system recognition, offering patients better outcomes with fewer side effects.
- Belzutifan showed a clinically meaningful 2.66-month improvement in quality-adjusted time without symptoms or toxicity (Q-TWiST) compared to everolimus in advanced renal cell carcinoma patients. - The phase 3 LITESPARK-005 trial demonstrated an 11.32% relative gain in Q-TWiST with belzutifan, despite numerically longer time with grade 3/4 toxicity. - Belzutifan patients experienced significantly longer time without symptoms and progression (10.73 vs 6.07 months) driven by prolonged periods without disease progression. - The analysis supports belzutifan's clinical benefit profile, with lead investigator Thomas Powles noting superior response rates, progression-free survival, and quality of life outcomes.
- A retrospective analysis of 14 solar urticaria cases shows higher prevalence in women (57.14%), with rapid symptom onset within 15 minutes and resolution typically within 2 hours. - UVA alone (35.71%) and UVA combined with visible light (28.57%) were identified as the primary triggers, with all patients showing partial improvement with antihistamines and sunscreen. - Omalizumab demonstrated effectiveness as a treatment option, with patients requiring either 150mg or 300mg doses every 28 days for symptom control.
• UK researchers have developed Triple T (Targeted Thermal Therapy), a groundbreaking 20-minute minimally invasive procedure that treats primary aldosteronism without removing the adrenal gland. • The FABULAS trial demonstrated Triple T's safety and effectiveness in 28 patients, with most achieving normal hormone levels after six months and many discontinuing blood pressure medications. • This innovative treatment could potentially help millions worldwide, as primary aldosteronism affects 1 in 20 people with high blood pressure but is currently underdiagnosed and undertreated.
- New research from the Stockholm Creatinine Measurements Project demonstrates that COVID-19 infection accelerates kidney function decline by 4.1 mL/min/1.73m2, significantly more than pneumonia. - Hospitalized COVID-19 patients experienced a more pronounced decline in estimated glomerular filtration rate (eGFR), with a 5.4% annual reduction compared to 2.3% in pneumonia patients. - Approximately 30% of COVID-19 hospitalizations result in acute kidney injury, highlighting the need for enhanced kidney function monitoring in severe COVID-19 patients.
- Queen Mary University of London is leading a global trial testing a six-monthly injection as an alternative to daily blood pressure tablets for hypertension treatment. - The study involves 630 patients worldwide, including 100 from the UK, and is funded by Alnylam Pharmaceuticals with support from the National Institute for Health and Care Research. - Researchers hope the subcutaneous injection could provide a more convenient treatment option for the estimated one-third of UK adults who have high blood pressure. - If successful, the treatment could offer significant benefits for patients who currently require daily medication to reduce their risk of heart attacks and strokes.
